Evidence map›Paper›PMID 38316462›Full record

ArticleLife science alliance2024

Stability of gut microbiome after COVID-19 vaccination in healthy and immuno-compromised individuals.

Rebecca H Boston, Rui Guan, Lajos Kalmar, Sina Beier, Emily C Horner, Nonantzin Beristain-Covarrubias, Juan Carlos Yam-Puc, Pehuén Pereyra Gerber, Luisa Faria, Anna Kuroshchenkova and 18 more

Abstract read
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Microbiome and Long COVID-19: Current Evidence and Insights.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Rebecca H BostonMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0002-4991-3391
Rui GuanMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0003-0862-2368
Lajos KalmarMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0003-3691-8350
Sina BeierMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0002-8230-4256
Emily C HornerMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0003-2226-1028
Nonantzin Beristain-CovarrubiasMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0002-4828-5282
Juan Carlos Yam-PucMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0003-4395-8844
Pehuén Pereyra GerberCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
Luisa FariaMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.
Anna KuroshchenkovaMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.
Anna E LindellMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0003-4734-5287
Sonja BlascheMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0001-9422-0474
Andrea Correa-NogueraDepartment of Clinical Immunology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
Anne ElmerNIHR Cambridge Clinical Research Facility, Cambridge, UK.
Caroline SaundersNIHR Cambridge Clinical Research Facility, Cambridge, UK.
Areti BermperiNIHR Cambridge Clinical Research Facility, Cambridge, UK.
Sherly JoseNIHR Cambridge Clinical Research Facility, Cambridge, UK.
Nathalie KingstonNIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
CITIID-NIHR COVID-19 BioResource Collaboration
Sofia GrigoriadouDepartment of Clinical Immunology, Barts Health, London, UK.
Emily StaplesMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.
Matthew S BucklandDepartment of Clinical Immunology, Barts Health, London, UK.ORCID https://orcid.org/0000-0002-5646-4707
Sara LearDepartment of Clinical Immunology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
Nicholas J MathesonCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
Vladimir BenesEuropean Molecular Biology Laboratory, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-0352-2547
Christine ParkinsonDepartment of Clinical Immunology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
James Ed ThaventhiranMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK jedt2@mrc-tox.cam.ac.uk.ORCID https://orcid.org/0000-0001-8616-074X
Kiran R PatilMedical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK kp533@mrc-tox.cam.ac.uk.ORCID https://orcid.org/0000-0002-6166-8640

Funding

Medical Research Council MC_UU_00025/11
6 · The paper itself

Abstract

Bidirectional interactions between the immune system and the gut microbiota are key contributors to various physiological functions. Immune-associated diseases such as cancer and autoimmunity, and efficacy of immunomodulatory therapies, have been linked to microbiome variation. Although COVID-19 infection has been shown to cause microbial dysbiosis, it remains understudied whether the inflammatory response associated with vaccination also impacts the microbiota. Here, we investigate the temporal impact of COVID-19 vaccination on the gut microbiome in healthy and immuno-compromised individuals; the latter included patients with primary immunodeficiency and cancer patients on immunomodulating therapies. We find that the gut microbiome remained remarkably stable post-vaccination irrespective of diverse immune status, vaccine response, and microbial composition spanned by the cohort. The stability is evident at all evaluated levels including diversity, phylum, species, and functional capacity. Our results indicate the resilience of the gut microbiome to host immune changes triggered by COVID-19 vaccination and suggest minimal, if any, impact on microbiome-mediated processes. These findings encourage vaccine acceptance, particularly when contrasted with the significant microbiome shifts observed during COVID-19 infection.

Indexed as

COVID-19Gastrointestinal MicrobiomeNeoplasmsCOVID-19 VaccinesHumansVaccinationCOVID-19 Vaccines

Identifiers

PMID38316462
PMCPMC10844540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.